Whitehawk Therapeutics (WHWK) Other Non-Current Liabilities (2020 - 2024)
Whitehawk Therapeutics' (WHWK) quarterly Other Non-Current Liabilities came in at $202000.0 in Q4 2024, down 48.6% on a QoQ basis from $393000.0 in Q3 2024.
Whitehawk Therapeutics (WHWK) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 3 years of Other Non-Current Liabilities data on file, last reported at $202000.0 in Q4 2024.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $202000.0 in Q4 2024; TTM through Dec 2024 was $202000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $202000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2024 stood at $202000.0, down from $393000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for WHWK reached as high as $393000.0 in Q3 2024 and fell as low as $97000.0 in Q4 2020.
- Historically, Other Non-Current Liabilities has averaged $200250.0 across 3 years, with a median of $155500.0 in 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Whitehawk Therapeutics | 34.18 Mn | 34.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2022 | 109,000.00 |
| Dec 31, 2020 | 97,000.00 |